China Pharma Holdings, Inc. (CPHI)
After hours:
| Previous Close | 0.2350 |
| Open | 0.2310 |
| Bid | 0.2360 x 1000 |
| Ask | 0.2479 x 1000 |
| Day's Range | 0.2309 - 0.2499 |
| 52 Week Range | 0.1700 - 1.1500 |
| Volume | |
| Avg. Volume | 321,529 |
| Market Cap | 4.255M |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9200 |
| Earnings Date | May 14, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireChina Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that through Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), our wholly owned subsidiary, it expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China.
PR NewswireChina Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-302.
